 | Oppenheimer Analysts Give Biohaven Pharmaceutical (NYSE:BHVN) a $67.00 Price Target
www.americanbankingnews.com - October 11 at 8:57 PM |
 | Biohaven Pharmaceutical Holding Company Ltd.
www.fool.com - October 10 at 7:41 PM |
| Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Expected to Post Earnings of -$2.03 Per Share
www.americanbankingnews.com - October 2 at 9:37 PM |
| Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 6:37 AM |
| Biohaven Pharmaceutical's (BHVN) "Buy" Rating Reaffirmed at William Blair
www.americanbankingnews.com - September 20 at 8:17 PM |
 | Biohaven and Ra Pharma drugs selected for innovative ALS study
seekingalpha.com - September 18 at 11:03 AM |
 | Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
finance.yahoo.com - September 18 at 11:03 AM |
| Biohaven completes enrollment in Phase 2/3 study of migraine med vazegepant
seekingalpha.com - September 10 at 11:55 AM |
| Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session
finance.yahoo.com - September 10 at 11:55 AM |
| Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
finance.yahoo.com - September 10 at 11:55 AM |
| Biohaven up 7% on accelerated rimegepant timeline
seekingalpha.com - September 4 at 11:16 AM |
| Biohaven Pharmaceuticals: An Intriguing CNS Play
seekingalpha.com - August 23 at 6:44 PM |
| Biohaven Pharmaceutical: An Intriguing CNS Play
seekingalpha.com - August 23 at 6:44 PM |
| Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
finance.yahoo.com - August 8 at 7:24 PM |
| Biohaven hits enrollment target in late-stage study of rimegepant for migraine prevention
seekingalpha.com - August 7 at 7:19 PM |
| Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
finance.yahoo.com - August 7 at 8:38 AM |
| Late-stage study underway for Biohaven's verdiperstat in MSA
seekingalpha.com - July 31 at 7:08 PM |
| Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
finance.yahoo.com - July 31 at 8:09 AM |
| Release Your 'Inner Spock' When Investing in Biotech Stocks
finance.yahoo.com - July 24 at 7:08 PM |
| FDA rejects Biohaven's Nurtec application for ALS
seekingalpha.com - July 22 at 9:32 AM |
| Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
finance.yahoo.com - July 22 at 9:32 AM |
| Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod
finance.yahoo.com - July 20 at 10:24 AM |
 | The Week Ahead In Biotech: Pharma Earnings Pick Up Pace
feeds.benzinga.com - July 20 at 10:15 AM |
| Biohaven reveals positive results in migrane drug trial
finance.yahoo.com - July 17 at 5:42 PM |
| Biohaven up 5% on publication of late-stage data on migraine med Zydis
seekingalpha.com - July 15 at 5:56 PM |
 | BHVN Crosses Above Key Moving Average Level
www.nasdaq.com - July 15 at 5:56 PM |
| Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
finance.yahoo.com - July 15 at 9:19 AM |
| Biohaven's rimegepant successful in third late-stage migraine study
seekingalpha.com - July 11 at 9:08 AM |
| Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
finance.yahoo.com - July 11 at 9:08 AM |
| Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
finance.yahoo.com - July 11 at 9:08 AM |
| Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
finance.yahoo.com - July 10 at 5:50 PM |
| 2 Single Hitters That Could Score With the 'Write' Strategy
finance.yahoo.com - July 10 at 9:16 AM |
| Biohaven Offering Seems to Make Sale Less Likely
finance.yahoo.com - July 5 at 5:32 PM |
| Enrollment underway in mid-stage study of Biohaven's rimegepant in chronic pain condition
seekingalpha.com - July 1 at 5:45 PM |
| Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
finance.yahoo.com - July 1 at 9:16 AM |
| Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
finance.yahoo.com - June 24 at 5:05 PM |
| Biohaven prices stock offering
seekingalpha.com - June 19 at 7:41 AM |
| Biohaven Pharma -30% as public offering dampens takeover speculation
seekingalpha.com - June 18 at 5:18 PM |
| BHVN Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - June 18 at 5:18 PM |
| BHVN and DGLY among premarket losers
seekingalpha.com - June 18 at 5:18 PM |
| Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit?
finance.yahoo.com - June 18 at 5:18 PM |
| Biohaven Pharma -13.4% after mixed shelf registration
seekingalpha.com - June 17 at 11:57 PM |
| Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
www.nasdaq.com - June 11 at 6:14 PM |
| Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies
finance.yahoo.com - May 17 at 6:54 PM |
| Biohaven Pharmaceutical (BHVN) Presents At American Academy of Neurology Annual Meeting - Slideshow
seekingalpha.com - May 10 at 6:07 PM |
| Biohaven's migraine med rimegepant shows positive effect when dosed on schedule
seekingalpha.com - May 8 at 9:15 AM |
| Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
finance.yahoo.com - May 7 at 9:13 AM |
| Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
finance.yahoo.com - May 3 at 9:22 AM |
| Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
finance.yahoo.com - May 2 at 7:05 PM |
| Interesting BHVN Put And Call Options For June 21st
www.nasdaq.com - April 30 at 6:11 PM |
